stockrow
Saturday 7 November 2026
Export EYPT’s income statement to Excel — free account
EyePoint, Inc.
EYPT Healthcare Biotechnology
EyePoint, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $31.4 million, down 27.5% from fiscal 2024.
- Revenue
- −90.5%
- EPS
- −28.2%
- Free cash flow
- +0.41%
Quarter to June 2026, against a year earlier
0.36
0.00
0.00%
Follow EYPT
Alert me
EyePoint, Inc. (EYPT) P/E ratio
EyePoint, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 21.5× (December 2015) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 38 more quarters | Free account |
Against its own ten years
Low 0.0×
High 21.5×
Ten-year median
0.0×
Current reading's percentile
92
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| IRLA IRulya Therapeutics Inc. compare | n/m |
| ANVS Annovis Bio, Inc. compare | n/m |
| BCTX BRIACELL THERAP compare | n/m |
| INMB INmune Bio, Inc. compare | n/m |
| NNVC NanoViricides, Inc. compare | n/m |
| PMN Promis Neurosciences compare | n/m |
| LITS Lite Strategy, Inc. compare | n/m |
| EYPT EyePoint, Inc. | n/m |
| EDSA Edesa Biotech, Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)